Mogamulizumab Tops Standard of Care for CTCL.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2018-001
Abstract: In the large international phase III MAVORIC trial, patients with previously treated cutaneous T-cell lymphoma who received the anti-CCR4 monoclonal antibody mogamulizumab experienced significantly longer progression-free survival and higher response rates, as well as better… read more here.
Keywords: mogamulizumab tops; mogamulizumab; standard care; tops standard ... See more keywords